Chinese biopharma stocks advanced Monday after a report that the U.S. may allow most drug licensing agreements with Chinese companies to continue. Innovent Biologics rose 7% and Akeso gained 8%. The reported approach would place biopharma on a different regulatory track from artificial intelligence and semiconductors, where the U.S. has tightened restrictions on China. Almost half of U.S. overseas drug-licensing deals in 2025 involved Chinese companies, while China signed licensing agreements worth $110 billion in the first half of 2026. An earlier description of the reported framework said it would exclude sensitive biotechnology related to pathogens.